Literature DB >> 30652551

Microsimulation Modeling in Oncology.

Çağlar Çağlayan1, Hiromi Terawaki1, Qiushi Chen1, Ashish Rai1, Turgay Ayer1, Christopher R Flowers1.   

Abstract

PURPOSE: Microsimulation is a modeling technique that uses a sample size of individual units (microunits), each with a unique set of attributes, and allows for the simulation of downstream events on the basis of predefined states and transition probabilities between those states over time. In this article, we describe the history of the role of microsimulation in medicine and its potential applications in oncology as useful tools for population risk stratification and treatment strategy design for precision medicine.
METHODS: We conducted a comprehensive and methodical search of the literature using electronic databases-Medline, Embase, and Cochrane-for works published between 1985 and 2016. A medical subject heading search strategy was constructed for Medline searches by using a combination of relevant search terms, such as "microsimulation model medicine," "multistate modeling cancer," and "oncology."
RESULTS: Microsimulation modeling is particularly useful for the study of optimal intervention strategies when randomized control trials may not be feasible, ethical, or practical. Microsimulation models can retain memory of prior behaviors and states. As such, it allows an explicit representation and understanding of how various processes propagate over time and affect the final outcomes for an individual or in a population.
CONCLUSION: A well-calibrated microsimulation model can be used to predict the outcome of the event of interest for a new individual or subpopulations, assess the effectiveness and cost effectiveness of alternative interventions, and project the future disease burden of oncologic diseases. In the growing field of oncology research, a microsimulation model can serve as a valuable tool among the various facets of methodology available.

Entities:  

Mesh:

Year:  2018        PMID: 30652551      PMCID: PMC6386553          DOI: 10.1200/CCI.17.00029

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN: 2473-4276


  22 in total

1.  Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.

Authors:  Andrew H Briggs; Milton C Weinstein; Elisabeth A L Fenwick; Jonathan Karnon; Mark J Sculpher; A David Paltiel
Journal:  Value Health       Date:  2012 Sep-Oct       Impact factor: 5.725

2.  Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.

Authors:  Reka Pataky; Roman Gulati; Ruth Etzioni; Peter Black; Kim N Chi; Andrew J Coldman; Tom Pickles; Scott Tyldesley; Stuart Peacock
Journal:  Int J Cancer       Date:  2014-02-04       Impact factor: 7.396

3.  Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.

Authors:  Roman Gulati; John L Gore; Ruth Etzioni
Journal:  Ann Intern Med       Date:  2013-02-05       Impact factor: 25.391

4.  Calibration of disease simulation model using an engineering approach.

Authors:  Chung Yin Kong; Pamela M McMahon; G Scott Gazelle
Journal:  Value Health       Date:  2009-01-12       Impact factor: 5.725

5.  Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.

Authors:  Rafael Meza; Kevin ten Haaf; Chung Yin Kong; Ayca Erdogan; William C Black; Martin C Tammemagi; Sung Eun Choi; Jihyoun Jeon; Summer S Han; Vidit Munshi; Joost van Rosmalen; Paul Pinsky; Pamela M McMahon; Harry J de Koning; Eric J Feuer; William D Hazelton; Sylvia K Plevritis
Journal:  Cancer       Date:  2014-02-27       Impact factor: 6.860

6.  Initial management strategies for follicular lymphoma.

Authors:  Qiushi Chen; Turgay Ayer; Loretta J Nastoupil; Miray Seward; Hongzheng Zhang; Rajni Sinha; Christopher R Flowers
Journal:  Int J Hematol Oncol       Date:  2012-10

7.  Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms.

Authors:  Jeanne S Mandelblatt; Kathleen A Cronin; Stephanie Bailey; Donald A Berry; Harry J de Koning; Gerrit Draisma; Hui Huang; Sandra J Lee; Mark Munsell; Sylvia K Plevritis; Peter Ravdin; Clyde B Schechter; Bronislava Sigal; Michael A Stoto; Natasha K Stout; Nicolien T van Ravesteyn; John Venier; Marvin Zelen; Eric J Feuer
Journal:  Ann Intern Med       Date:  2009-11-17       Impact factor: 25.391

8.  Five-year risk of colorectal neoplasia after negative screening colonoscopy.

Authors:  Thomas F Imperiale; Elizabeth A Glowinski; Ching Lin-Cooper; Gregory N Larkin; James D Rogge; David F Ransohoff
Journal:  N Engl J Med       Date:  2008-09-18       Impact factor: 91.245

9.  The development and validation of a decision-analytic model representing the full disease course of acute myeloid leukemia.

Authors:  Annemieke Leunis; W Ken Redekop; Kees A G M van Montfort; Bob Löwenberg; Carin A Uyl-de Groot
Journal:  Pharmacoeconomics       Date:  2013-07       Impact factor: 4.981

10.  The Population Health Model (POHEM): an overview of rationale, methods and applications.

Authors:  Deirdre A Hennessy; William M Flanagan; Peter Tanuseputro; Carol Bennett; Meltem Tuna; Jacek Kopec; Michael C Wolfson; Douglas G Manuel
Journal:  Popul Health Metr       Date:  2015-09-03
View more
  8 in total

1.  Mailed FIT (fecal immunochemical test), navigation or patient reminders? Using microsimulation to inform selection of interventions to increase colorectal cancer screening in Medicaid enrollees.

Authors:  Melinda M Davis; Siddhartha Nambiar; Maria E Mayorga; Eliana Sullivan; Karen Hicklin; Meghan C O'Leary; Kristen Dillon; Kristen Hassmiller Lich; Yifan Gu; Bonnie K Lind; Stephanie B Wheeler
Journal:  Prev Med       Date:  2019-10-18       Impact factor: 4.018

2.  Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.

Authors:  Ross F Harrison; Scott B Cantor; Charlotte C Sun; Mariana Villanueva; Shannon N Westin; Nicole D Fleming; Iakovos Toumazis; Anil K Sood; Karen H Lu; Larissa A Meyer
Journal:  Gynecol Oncol       Date:  2021-01-31       Impact factor: 5.482

3.  Estimating the future cancer management costs attributable to modifiable risk factors in Canada.

Authors:  Yibing Ruan; Abbey E Poirier; Joy Pader; Keiko Asakawa; Chaohui Lu; Saima Memon; Anthony B Miller; Stephen D Walter; Paul J Villeneuve; Will D King; Karena D Volesky; Leah Smith; Prithwish De; Christine M Friedenreich; Darren R Brenner
Journal:  Can J Public Health       Date:  2021-05-25

4.  Bayesian versus Empirical Calibration of Microsimulation Models: A Comparative Analysis.

Authors:  Stavroula A Chrysanthopoulou; Carolyn M Rutter; Constantine A Gatsonis
Journal:  Med Decis Making       Date:  2021-05-08       Impact factor: 2.749

5.  The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study.

Authors:  Abraham M Getaneh; Eveline A M Heijnsdijk; Harry J de Koning
Journal:  Sci Rep       Date:  2021-01-19       Impact factor: 4.379

6.  Projecting the prevalence of obesity in South Korea through 2040: a microsimulation modelling approach.

Authors:  Yoon-Sun Jung; Young-Eun Kim; Dun-Sol Go; Seok-Jun Yoon
Journal:  BMJ Open       Date:  2020-12-30       Impact factor: 2.692

7.  The EU-TOPIA evaluation tool: An online modelling-based tool for informing breast, cervical, and colorectal cancer screening decisions in Europe.

Authors:  Andrea Gini; Nicolien T van Ravesteyn; Erik E L Jansen; Eveline A M Heijnsdijk; Carlo Senore; Ahti Anttila; Dominika Novak Mlakar; Piret Veerus; Marcell Csanádi; Nadine Zielonke; Sirpa Heinävaara; György Széles; Nereo Segnan; Harry J de Koning; Iris Lansdorp-Vogelaar
Journal:  Prev Med Rep       Date:  2021-04-30

8.  Extending analytic methods for economic evaluation in implementation science.

Authors:  Meghan C O'Leary; Kristen Hassmiller Lich; Leah Frerichs; Jennifer Leeman; Daniel S Reuland; Stephanie B Wheeler
Journal:  Implement Sci       Date:  2022-04-15       Impact factor: 7.960

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.